A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 7682710.
- Also identified by PMC identifier 46337.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A potential new approach for gene therapy against human immunodeficiency virus type 1 (HIV-1) infection is the design of a nonstructural gene-based virion-specific inhibitory molecule that is packaged with virus to destroy its infectivity. We tested this approach for HIV-1 by using Vpx, a virion-associated protein of HIV-2 and simian immunodeficiency virus. Vpx was incorporated into HIV-1 virions and the resulting cell-free virus lost infectivity in CD4+ human T cells. This demonstrates the therapeutic potential of an accessory gene-based virion-specific inhibitory molecule. Vpx and its derivatives can be regarded as a new class of anti-HIV-1 molecule.
Medical subject headings
- Acquired Immunodeficiency Syndrome
- Gene Products, vpr
- Genetic Therapy
- Genome, Viral
- HIV-1
- T-Lymphocytes
- Viral Regulatory and Accessory Proteins
- Virion